93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 32; p. S1414
Main Authors Makharadze, T., Quek, R.G., Melkadze, T., Gogishvili, M., Ivanescu, C., Giorgadze, D., Dvorkin, M., Penkov, K., Laktionov, K., Nemsadze, G., Nechaeva, M., Rozhkova, I., Kalinka, E., Gessner, C., Moreno-Jaime, B., Passalacqua, R., Konidaris, G., Rietschel, P., Gullo, G.
Format Journal Article
LanguageEnglish
Published 01.12.2021
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1016/j.annonc.2021.10.111